Loading...
Loading...
XOMA| Name | Value |
|---|---|
| Revenues | 1,833.0K |
| Cost of Revenue | 225.0K |
| Gross Profit | 1,608.0K |
| Operating Expense | 7,289.0K |
| Operating I/L | -5,681.0K |
| Other Income/Expense | -175.0K |
| Interest Income | 447.0K |
| Pretax | -20,109.0K |
| Income Tax Expense | -8,647.0K |
| Net Income/Loss | -20,109.0K |
XOMA Corporation operates as a biotechnology royalty aggregator, acquiring the potential future economics associated with pre-commercial therapeutic candidates licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets, and it helps biotech companies enhance human health by providing financial support in exchange for future royalties from successful products.
